The New York State Assembly held its first-ever public hearing on the potential therapeutic use of psilocybin, the psychoactive compound found in certain mushrooms. Organized by the Assembly Committee on Health and chaired by Assemblywoman Amy Paulin, the event brought together medical professionals, advocates, researchers, and individuals with firsthand experience to discuss the compound’s possible medical applications and regulatory future.
Advocates highlighted psilocybin’s growing reputation as a promising treatment for conditions that are often resistant to conventional therapies, including depression, post-traumatic stress disorder, anxiety, and chronic pain. Many speakers urged lawmakers to create a regulated framework that balances patient access with safety and scientific oversight.
Among the most compelling testimonies came from Joseph McKay, a retired New York City firefighter and survivor of the September 11th attacks. McKay shared that traditional medical treatments had failed to relieve his severe cluster headaches, but controlled psilocybin use brought significant relief. He urged legislators to establish a legal path for patients to access psilocybin under supervision.
However, not all testimony favored legalization. Critics, including medical experts and policy analysts, cautioned that research remains limited and that rushing legalization could lead to unintended consequences. Concerns were raised about long-term safety, potential misuse, and the absence of federal approval or standardized clinical guidelines. Legislators also discussed how psilocybin might be monitored, distributed, and integrated into existing healthcare systems.
Assemblywoman Paulin noted that New York would join Oregon and Colorado as one of only a few states to formally consider regulated medicinal psilocybin programs. Her proposal would allow patients to obtain up to two ounces of psilocybin mushrooms per month from licensed cultivators, following appropriate medical screening. Another proposal by Assemblyman Patrick Burke would establish a certification system for facilitators, such as doctors and therapists, to administer psilocybin-assisted therapy.
The hearing marks an important milestone in New York’s exploration of psychedelic reform and its potential role in mental health treatment. As lawmakers continue to weigh scientific evidence and public testimony, the discussion reflects a broader national shift toward reevaluating psychedelics as legitimate tools for healing rather than as criminal substances.
Dabbin-Dad Newsroom
